Question: In the revised USP <795> Pharmaceutical Compounding?Nonsterile Preparations:
1. Why is there a loss of one day in the BUDs?
2. Why is the day the preparation is compounded considered as
"Day 1" in USP <795> but as "Day 0" in USP <797>?
3. Why the inconsistency between the two chapters?
Before answering, let's see what USP <795> says:
10. ESTABLISHING BEYOND-USE DATES
10.3 Establishing a BUD for a CNSP
The BUDs indicate the days after the CNSP is prepared and beyond which the CNSP must not be used. The day that the preparation is compounded is considered Day 1. The BUDs in Table 3 [of USP <795>] are based on the ability of the CNSP to maintain chemical and physical stability and to suppress microbial growth...
Answer:
Stability should begin with the compounding of the preparation as "Day 0," as it is reported routinely in scientific stability studies and is the industry standard. A compounded preparation should NOT lose a day of its BUD by this arbitrary assignment of the "day of compounding is considered Day 1."
Comments:
In the revised <795>, it is not clear or explained why the day a preparation is compounded is assigned as "Day 1" and not "Day 0". This is not the same in sterile compounding <797>. In <797>, a day is stated to be 24 hours. The starting point of any scientific study, etc., is "Day 0." Patients should not be penalized for this arbitrary shortening of the BUD. Also, if the day of compounding was "Day 1" in <797>, the BUD for a Category 1 CSP [Table 10 of USP <797>], which is 12 hours, would be out-of-date as soon as it was compounded.
Another Question: In USP <795>, 10.1 Terminology, the first sentence states:
Each CNSP label must state the date, or the hour and date, beyond which the preparation cannot be used and must be discarded (i.e., the BUD).
Answer:
Probably a minor point but Table 3 in <795> ONLY lists "days" and not hours. The word "hours" is only mentioned in <797> so why is it mentioned here? Is it necessary to change Beyond-Use Date to Beyond-Use Date and Time? Not sure patients would really comply and is it really "clinically significant" since most compounded preparations appear to be stable past their assigned BUDs as shown in most stability studies? (Note: Also of interest regarding Expiration Dates, see the EpiPen story below).
Next week we will begin a discussion on the use of Water Activity (Aw) the way it is applied in <795>.
Editor's Note: For those state boards of pharmacy that are NOT adopting any or all of these chapters and preparing their own or using their own modifications of the chapters, it is important that all pharmacists within the individual states clearly read, understand, and implement those state laws and regulations affecting them.
A simplified/alternative version of both <795> and <797> will soon be available for state boards of pharmacy to modify and develop for their individual states.
Also, don't forget, an informal commentary has been prepared on the final version of USP <797> and is available for a FREE download for all on the Homepage at:
www.CompoundingToday.com
Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
International Journal of Pharmaceutical Compounding
Remington: The Science and Practice of Pharmacy Twenty-second edition
|